Physician profile
Amy Teresi
NPI 1265498703
$19,625.17
in general payments reported to CMS, 2019-2025
57 companies · $2,765 in 2025
The $2,765 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,299 · 2020: $2,773 · 2021: $2,865 · 2022: $2,557 · 2023: $3,052 · 2024: $2,315 · 2025: $2,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,123 · Travel and Lodging: $8.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,123.02 |
| Travel and Lodging | $8.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,982.44 | 2019-2025 | Evenity, Tepezza, Repatha |
| Lilly USA, LLC | $1,802.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,786.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,671.13 | 2019-2025 | Ubrelvy, Synthroid |
| Corcept Therapeutics | $1,291.99 | 2019-2025 | Korlym |
| Horizon Therapeutics Plc | $932.50 | 2019-2023 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $812.19 | 2019-2022 | |
| Abbott Laboratories | $711.85 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $616.88 | 2021-2025 | |
| Ibsa Pharma INC. | $508.68 | 2019-2025 | Tirosint, Licart, Tirosint |
| Mannkind Corporation | $467.36 | 2019-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.63 | 2019-2025 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $422.48 | 2019-2021 | |
| Dexcom, INC. | $421.25 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $418.27 | 2019-2023 | Belsomra, Steglatro, Verquvo |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Teresi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.